Evidence map›Paper›PMID 39948520›Full record

ArticleBMC nephrology2025

Norwegian kidney biopsy biobank (NorKiBB): organization, baseline characteristics, and generalizability of a low-cost national biobank.

Marius Altern Øvrehus, Knut Asbjørn Rise Langlo, Sabine Leh, Øystein Eikrem, Solfrid Romundstad, Håvard Aksnes, Ingjerd Wangensteen Manner, Christian Aalborg, Marit D Solbu, Lasse G Gøransson and 4 more

Erratum issuedAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Marius Altern ØvrehusDepartment of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway. marius.altern.ovrehus@ntnu.no.
Knut Asbjørn Rise LangloDepartment of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway.
Sabine LehDepartment of Pathology, Haukeland University Hospital, Bergen, Norway.
Øystein EikremDepartment of Nephrology, Haukeland University Hospital, Bergen, Norway.
Solfrid RomundstadDepartment of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway.
Håvard AksnesDepartment of Internal Medicine, Nephrology Unit, Lillehammer Hospital, Lillehammer, Norway.
Ingjerd Wangensteen MannerDepartment of Nephrology, Oslo University Hospital, Ullevål, Oslo, Norway.
Christian AalborgDepartment of Nephrology, Akershus Oslo University Hospital, Akershus Universitetssykehus, Lørenskog, Norway.
Marit D SolbuDepartment of Nephrology, University Hospital of North Norway, Tromsø, Norway.
Lasse G GøranssonDepartment of Nephrology, Stavanger University Hospital, Stavanger, Norway.
Hans-Peter MartiDepartment of Nephrology, Haukeland University Hospital, Bergen, Norway.
Michael G ShlipakDepartment of Medicine, San Francisco Veterans Affairs Healthcare System, Kidney Health Research Collaborative of San Francisco, University of California, San Francisco, CA, USA.
Joachim H IxDivision of Nephrology-Hypertension, Department of Medicine, San Diego, and Veterans Affairs San Diego Healthcare System, University of California, San Diego, CA, USA.
Stein I HallanDepartment of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBiobanks that hold blood, urine and kidney tissue are key for translational nephrology research but are few and have limited availability. We describe the organization, baseline characteristics, and generalizability of a low-cost national biobank. MATERIALS AND

methodsEight Norwegian hospitals participated in this multi-center, prospective cohort study and biobank initiative. Patients referred for routine clinical native kidney biopsies were eligible for inclusion, starting September 2020. Extensive information on medical history and risk factors were collected into an encrypted on-line database by the treating nephrologist. A comprehensive standardized panel of blood and urine tests were analyzed in the clinical routine and registered along with the full histology report. Extra urine and blood samples were collected, aliquoted and prepared locally within two hours, frozen at -80 C, and later sent to a central government-funded biorepository together with remaining kidney biopsy material.

resultsBy September 2023, a total of 633 patients were included out of 1050 eligible patients. Mean age was 52.6 years (SD 18.7), 384 (61%) were men, and participants displayed a wide spectrum of kidney disease with mean estimated glomerular filtration rate (eGFR) 53 mL/min/1.73m DISCUSSION: We demonstrate the feasibility of establishing a large national kidney biopsy biobank across a variety of clinical and histopathologic diagnoses. Blood and urine were stored, accompanied by kidney tissue, at a moderate cost due to a combination of a dedicated nephrology workforce, routine clinical care, and established biobank facilities.

Indexed as

Biological Specimen BanksKidneyKidney DiseasesAdultAgedBiopsyFemaleHumansMaleMiddle AgedNorwayProspective StudiesBiobankChronic kidney diseaseEpidemiologyGlomerulonephritisKidney biopsy

Identifiers

PMID39948520
PMCPMC11827217

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.